WO2024161311 - TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION
National phase entry is expected:
Publication Number
WO/2024/161311
Publication Date
08.08.2024
International Application No.
PCT/IB2024/050860
International Filing Date
30.01.2024
Title **
[English]
TREATMENT OF BETA-CELL FAILURE OR DYSFUNCTION
[French]
TRAITEMENT DE L'INSUFFISANCE OU DU DYSFONCTIONNEMENT DES CELLULES BÊTA
Applicants **
NOVMETAPHARMA CO., LTD.
13th Floor, Trees Building, 727, Eonju-ro, Gangnam-gu
Seoul 06050, KR
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
291 Daehak-ro, Yuseong-gu
Daejeon, KR
Inventors
KIM, Hail
20 Daedeok-daero 653beon-gil, Yuseong-gu
Daejeon, KR
JUNG, Hoeyune
101-801, 394, Jigok-ro, Nam-gu
Pohang-si
Gyeongsangbuk-do 37668, KR
KIM, Kyun Hoo
109-1802, 300 Munji-ro, Yuseong-gu
Daejeon, KR
LEE, Joonyub
4002,222 Banpo-daero, Seocho-gu
Seoul, KR
LEE, Hyeonkyu
205,291 Daehak-ro, Yuseong-gu
Daejeon, KR
LEE, Heon Jong
451-2004, Crystal-ro 74beon-gil 26, Seo-gu
Incheon, KR
Priority Data
63/482,357
31.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1649 | |
| EPO | Filing, Examination | 8904 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 3310 |
Total: 15032 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
A method and composition for treating and/or preventing β-cell dysfunction and/or protecting impaired β-cells are disclosed. The method includes administering an effective amount of cyclo (his-pro) (CHP), alone or with zinc, to a subject. The composition contains an effective amount of cyclo (his-pro) (CHP) as an active ingredient. The composition may further contain zinc and/or other antidiabetic agent, or can be administered in combination with zinc and/or other antidiabetic agent.[French]
L'invention concerne une méthode et une composition pour traiter et/ou prévenir un dysfonctionnement des cellules β et/ou protéger des cellules β altérées. La méthode comprend l'administration à un sujet d'une quantité efficace de cyclo(his-pro) (CHP), seule ou avec du zinc. La composition contient une quantité efficace de cyclo(his-pro) (CHP) en tant que principe actif. La composition peut contenir en outre du zinc et/ou un autre agent antidiabétique, ou peut être administrée en association avec du zinc et/ou un autre agent antidiabétique.